Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients - Wikidata - wikimedia - TriplyDB

Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients

Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients

http://www.wikidata.org/entity/Q30511886

about

Lamarckian evolution explains human brain evolution and psychiatric disorders Proteomics Research in Schizophrenia Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients.Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients.Theranostic Biomarkers for Schizophrenia Impaired metabolic reactivity to oxidative stress in early psychosis patients A three step network based approach (TSNBA) to finding disease molecular signature and key regulators: a case study of IL-1 and TNF-alpha stimulated inflammation.The use of clinical and biological characteristics to predict outcome following First Episode Psychosis.Altered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis.Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia Simvastatin augmentation for recent-onset psychotic disorder: A study protocol.The proteome of schizophrenia.Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.Realising stratified psychiatry using multidimensional signatures and trajectories.Blood test for schizophrenia.Systems biology, bioinformatics, and biomarkers in neuropsychiatry.The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients.Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.Blood-based biomarkers in depression: emerging themes in clinical research.Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses.Can proteomics-based diagnostics aid clinical psychiatry?Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia.The emergence of point-of-care blood-based biomarker testing for psychiatric disorders: enabling personalized medicine.Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms.Proteomics insight into psychiatric disorders: an update on biological fluid biomarkers.Proteomic Differences in Blood Plasma Associated with Antidepressant Treatment Response.Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots.Lab-on-a-Chip Proteomic Assays for Psychiatric Disorders.Phenotyping Multiple Subsets of Immune Cells In Situ in Formalin-Fixed, Paraffin-Embedded Tissue Sections.Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders.Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders.Identifying Biomarker Candidates in the Blood Plasma or Serum Proteome.The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.Depletion of Highly Abundant Proteins of the Human Blood Plasma: Applications in Proteomics Studies of Psychiatric Disorders.Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients.Maternal Diet, Metabolic State, and Inflammatory Response Exert Unique and Long-Lasting Influences on Offspring Behavior in Non-Human Primates.

P2860

Q21129357-12852B5E-5F0C-43F4-AE35-E65727F3B437 Q26766821-F3D368A4-8BD0-41EF-83DA-2BB6FD654F38 Q26771434-1B7F1270-2240-4BCA-851A-DF8E071E8558 Q27012892-2313F71E-221E-4876-A005-1CDFD05EC3A7 Q33451672-04D5F930-BE89-455C-B871-3074E513A61D Q33453744-A2808517-9AC2-46FB-8265-E1BD37F75E6D Q33624412-567E8DCA-6F35-4950-87BA-8085BC3383A2 Q34048645-6E0816A6-8CBF-427C-88A2-CF8479C65F25 Q35152688-979D8937-8F54-4D29-9426-E502FC2DCEF3 Q35457414-9366601C-8831-4023-908D-30A697E09BD1 Q35603078-3E278189-2C06-4B0E-9B2E-1655C68CDA7F Q36063627-30752C55-2C26-4B01-8E7F-192E23FCBD5E Q36324327-B9DED5A0-12A7-4A65-8BE0-67F8102247EC Q36848272-EEDD340F-AAEA-4477-86EE-10915AABC021 Q36998471-B39BBA73-2E39-4142-B0B5-5A2579C97CA7 Q37591548-0632C901-3BBD-4866-8637-A041A966092B Q38038106-FC741DC0-1FE5-474D-A358-4B4A1FA2ABA1 Q38069972-4680EEF5-7849-4C0C-B228-E357CD904970 Q38170139-FAF389BC-0550-4A6F-BE6F-CA32AB3B5FE3 Q38170140-23DD4D4C-32E5-4A37-905B-19B7868FAFF6 Q38219783-BDC8B4E0-75EE-4F81-A0EF-4E78F938D145 Q38366733-B628ACDF-A328-4984-AAD2-671702240376 Q38392369-27FD0B6A-5729-4E8C-A141-FE834D78BF9E Q38672722-4F301411-2021-4BC3-9B0F-DF7BBC45E40F Q38783299-72CBF827-737D-4072-81A6-B9757BD31C6C Q38805367-09298C93-917F-4676-A715-50D099C7A92D Q38939217-A46F9CCD-BBEE-4493-96C9-2AA5CE313F43 Q41605632-D651BE5C-31A9-4EE2-B779-3B880D8B3A06 Q41611297-975A3D9E-38BC-4F3E-A37C-7E059F36BCB6 Q47241901-26A39E09-1AE1-4CA2-BA2C-3CFD69E65041 Q47763172-B32DA7FE-978C-4478-A662-AB7EA6DA2D23 Q47763181-9EF2B7EC-F98B-4C70-970D-85BD84DE66B9 Q47763396-21E4141D-CEA9-4EE4-94A7-B39927C8BBAA Q47787773-C9B6DD84-3835-490A-9980-3EB7E44F2EC9 Q48239748-CF1C1F74-818F-45A9-8AEC-087CDC6D921C Q49481418-5AEFEB50-D8CE-4472-92AA-4C90EF11B662 Q50578956-B0C5A6F3-1D49-48D5-B8D3-0571FC46A5A1 Q51298241-2EAF4AD3-D7FA-46DF-B2E7-12DEA6373ADF Q54942497-032D201C-9910-4990-896C-BCB4CCF4B850 Q55024417-24A73968-14C8-46CD-80FD-0CCB290B9C4E

P2860

Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients

http://www.wikidata.org/entity/Q30511886

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Identification of blood-based ...... apse in schizophrenia patients

@ast

Identification of blood-based ...... apse in schizophrenia patients

@en

type

label

Identification of blood-based ...... apse in schizophrenia patients

@ast

Identification of blood-based ...... apse in schizophrenia patients

@en

prefLabel

Identification of blood-based ...... apse in schizophrenia patients

@ast

Identification of blood-based ...... apse in schizophrenia patients

@en

P1433

Q30511886-A23BA983-67B6-4FA5-A52F-9F690ED8681A

P1476

Q30511886-C6FFBFE6-F082-4360-9E4D-D577D35A9EC1

P2093

Q30511886-060D9E83-00CD-450D-B284-40860B553793

Q30511886-96A1A8F8-A03C-4A54-A785-121FAE433198

Q30511886-CF0A4711-4C3B-476C-B389-323CBC7CB707

P2860

Q30511886-0287AE9D-35E7-4606-847C-85F6529377AB

Q30511886-076A9752-DEAD-4417-82BB-E9CA1BD4D601

Q30511886-0A22BD3F-6201-4B52-B892-0E5B39ADB390

Q30511886-17F515AC-5503-4CEC-AA51-FCDB7C4AC30B

Q30511886-2B58AB40-5C98-4E6F-B731-9316D07E2A65

Q30511886-2CC1FF59-5CC2-43D4-A6FD-D8574E668A0B

Q30511886-3436E159-7FEC-4E49-8426-230AE9511CF5

Q30511886-4167C82D-4E28-45C6-8C83-68D989FEDE88

Q30511886-4DD4A359-6FDF-489F-A7FB-1B0B36611D4E

Q30511886-65BCF61F-3539-4501-A1F7-B9FC452D9A4A

P2888

Q30511886-24B23727-7F4C-4E7F-91F4-ACFC0972EAE0

P304

Q30511886-75EC85ED-B75A-49BD-9A6E-831371DB631C

P31

Q30511886-BC6690C5-AA42-4C8A-B7DC-3A3D799A81BD

P356

Q30511886-AECC040A-4159-4C6D-95F5-37F696995DAC

P478

Q30511886-C1D4DFF3-FB58-4A92-A3D5-F907620C899B

P50

Q30511886-857805E4-E0CC-40D6-9911-EA87B40EFCA5

Q30511886-E699CF7D-C2DB-4943-B5BF-50C0C9AC22C5

P577

Q30511886-EB781D40-B233-4053-A361-8B3D0BAEB441

P5875

Q30511886-BEBE4586-6656-4CCA-BA42-8248DD826A87

P6179

Q30511886-26AC6F32-3DED-414C-BA61-09395F1CAD22

P698

Q30511886-173614BB-5A45-4A96-A694-9A3FA79BA058

P921

Q30511886-57D5CB68-66EE-4E27-A88A-B1F6A171CC93

P932

Q30511886-2BE34EC3-5DAD-43A4-A039-BE6D3E78E0E7

P356

P1433

Translational Psychiatry

P1476

Identification of blood-based ...... apse in schizophrenia patients

@en

P2093

B Bogerts

http://www.w3.org/2001/XMLSchema#string

E Schwarz

http://www.w3.org/2001/XMLSchema#string

S Bahn

http://www.w3.org/2001/XMLSchema#string

P2860

Regression towards the mean

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.

Regression to the mean: what it is and how to deal with it.

Effects of atypical antipsychotics on weight and serum lipid levels.

Pharmacotherapy for treatment-resistant schizophrenia.

Modeling treatment-resistant depression.

Relationships between plasma leptin concentrations and human brain structure: a voxel-based morphometric study.

P2888

P304

e82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/TP.2012.3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230568535

http://www.w3.org/2001/XMLSchema#string

P6179

1018680924

http://www.w3.org/2001/XMLSchema#string

P698

22832819

http://www.w3.org/2001/XMLSchema#string

P921

P932

3309553

http://www.w3.org/2001/XMLSchema#string